The Fonds d’investissement Eurêka

Simmunome is a biotechnology company that operates as a contract research organization, specializing in the development of artificial intelligence-driven computational models. These models focus on the pathogenesis and immunogenesis of various diseases, particularly in oncology and the nervous system. By thoroughly annotating cellular interactions at a molecular level, Simmunome achieves high physiological accuracy in its models. The company addresses the inefficiencies associated with clinical trial success by transforming physiological systems into biologically representative simulations. Utilizing machine learning and integrating multi-omic data, Simmunome enhances the predictive accuracy of its models, allowing drug discovery and research organizations to better understand drug mechanisms, improve efficacy in targeted populations, and assess safety profiles effectively.